^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MUC16-targeted antibody-drug conjugate

    Related drugs:
    3years
    An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. (PubMed, Gynecol Oncol)
    In this Phase I study, DMUC4064A demonstrated a tolerable safety profile along with encouraging efficacy in the indication of platinum-resistant OC.
    Clinical • P1 data • PK/PD data • Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated) • MUC4 (Mucin 4, Cell Surface Associated)
    |
    MUC1 overexpression • MUC16 expression
    |
    RG7882